Alkaline Phosphatase and Hypophosphatasia.

Area of Science:

• Biochemistry
• Genetics
• Pediatric Medicine

Background:

• Hypophosphatasia (HPP) is a rare genetic disorder.
• It stems from mutations in the ALPL gene, causing deficient activity of tissue-non-specific alkaline phosphatase (TNAP).
• This deficiency leads to extracellular accumulation of inorganic pyrophosphate (PPi), inhibiting mineralization and causing skeletal and dental issues.

Purpose of the Study:

• To evaluate the efficacy of enzyme replacement therapy using mineral-targeted TNAP.
• To investigate the pathophysiology of severe HPP, including craniosynostosis and muscle weakness.
• To explore new treatment strategies for HPP.

Main Methods:

• Enzyme replacement therapy with mineral-targeted TNAP was administered to TNAP-knockout mice from birth.
• Clinical trials were conducted on infants and young children with life-threatening HPP.
• Ongoing clinical trials are investigating HPP pathophysiology and treatment outcomes.

Main Results:

• Enzyme replacement therapy prevented severe HPP in TNAP-knockout mice.
• The therapy rescued and substantially treated infants and young children with severe HPP.
• Clinical trials are providing insights into HPP pathophysiology, such as craniosynostosis and muscle weakness.

Conclusions:

• Enzyme replacement therapy with TNAP is a viable treatment for severe HPP.
• Further research is ongoing to understand HPP pathophysiology and develop improved treatments.
• Early intervention with TNAP enzyme replacement can significantly improve outcomes for HPP patients.